PE02232011A1 - Pyrrolo [2,3-e] [1,2,4] triazolo [4,3-a] pyrazine, as kinase inhibitors - Google Patents

Pyrrolo [2,3-e] [1,2,4] triazolo [4,3-a] pyrazine, as kinase inhibitors

Info

Publication number
PE02232011A1
PE02232011A1 PE2010001126A PE0011262010A PE02232011A1 PE 02232011 A1 PE02232011 A1 PE 02232011A1 PE 2010001126 A PE2010001126 A PE 2010001126A PE 0011262010 A PE0011262010 A PE 0011262010A PE 02232011 A1 PE02232011 A1 PE 02232011A1
Authority
PE
Peru
Prior art keywords
triazolo
pyrrolo
6h
yl
pyrazine
Prior art date
Application number
PE2010001126A
Other languages
Spanish (es)
Inventor
Neil Wishart
Maria A Argiriadi
David J Calderwood
Anna M Ericsson
Bryan A Fiamengo
Kristine E Frank
Michael Friedman
Erick R Goedken
Biqin C Li
Kent D Stewart
Jeffrey W Voss
Grier A Wallace
Lu Wang
Kevin R Woller
Michael J Morytko
Dawn M George
Nathan S Josephsohn
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US13159908P priority Critical
Priority to US13160208P priority
Priority to US19015908P priority
Priority to US20106408P priority
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of PE02232011A1 publication Critical patent/PE02232011A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41415363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE02232011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE T ES N, O, S, CR6; Referring to a heterocyclic compound of formula (I), wherein T is N, O, S, CR6; U ES NO CR4; U IS NOT CR4; X ES CR3 O NR3; X IS O CR3 NR3; Y ES NOC; AND YOU NOC; R1, R2 Y R5 SON H, -CN, HALOGENO, -CF3, ENTRE OTROS; R1, R2 and R5 are H, CN, halogen, -CF3, among others; R3 ES H, CICLOALQUILO C5-C12, CICLOALQUILO C3-C10, ENTRE OTROS; R3 is H, C5-C12cycloalkyl, C3-C10, among others; R4 Y R6 SON H, HALOGENO, CICLOALQUILO C5-C12, ENTRE OTROS. R4 and R6 are H, halogen, C5-C12, among others. SON COMPUESTOS PREFERIDOS: 1-(2-METILCICLOHEXIL)-6H-PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZINA, cis-4-(6H-PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN-1-IL)CICLOHEXAMINA, N-(4-(6H-PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN-1-IL)BICICLO[2,2,2]OCTAN-1-IL)-3-CLOROBECENSULFONAMIDA, ENTRE OTROS. They are preferred compounds: 1- (2-methylcyclohexyl) -6H-pyrrolo [2,3-e] [1,2,4] triazolo [4,3-a] pyrazine, cis -4- (6H-pyrrolo [2, 3-e] [1,2,4] triazolo [4,3-a] pyrazin-1-yl) Cyclohexylamine, N- (4- (6H-pyrrolo [2,3-e] [1,2,4] triazolo [4,3-a] pyrazin-1-yl) bicyclo [2.2.2] octan-1-yl) -3-CLOROBECENSULFONAMIDA, among others. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASAS Y SON UTILES EN EL TRATAMIENTO DEL CANCER, TRASTORNOS CARDIOVASCULARES, MELANOMA, ARTERIOSCLEROSIS, ENTRE OTROS Such compounds are kinase inhibitors and are useful in the treatment of cancer, CARDIOVASCULAR DISORDERS, MELANOMA, Arteriosclerosis, AMONG OTHERS
PE2010001126A 2008-06-10 2009-06-09 Pyrrolo [2,3-e] [1,2,4] triazolo [4,3-a] pyrazine, as kinase inhibitors PE02232011A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13159908P true 2008-06-10 2008-06-10
US13160208P true 2008-06-10 2008-06-10
US19015908P true 2008-08-26 2008-08-26
US20106408P true 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
PE02232011A1 true PE02232011A1 (en) 2011-05-07

Family

ID=41415363

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013001090A PE04072014A1 (en) 2008-06-10 2009-06-09 New tricyclic compounds
PE2010001126A PE02232011A1 (en) 2008-06-10 2009-06-09 Pyrrolo [2,3-e] [1,2,4] triazolo [4,3-a] pyrazine, as kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2013001090A PE04072014A1 (en) 2008-06-10 2009-06-09 New tricyclic compounds

Country Status (36)

Country Link
US (4) US8962629B2 (en)
EP (2) EP2299821B1 (en)
JP (2) JP5748659B2 (en)
KR (2) KR101718384B1 (en)
CN (2) CN102118968A (en)
AR (1) AR072086A1 (en)
AU (1) AU2009257602B2 (en)
BR (1) BRPI0915374A2 (en)
CA (2) CA3000973A1 (en)
CL (1) CL2010001426A1 (en)
CO (1) CO6382083A2 (en)
CR (1) CR20160007A (en)
CY (1) CY1117165T1 (en)
DK (1) DK2299821T3 (en)
DO (2) DOP2010000382A (en)
EC (1) ECSP10010657A (en)
ES (1) ES2559403T3 (en)
HK (1) HK1155617A1 (en)
HR (1) HRP20160098T1 (en)
HU (1) HUE028347T2 (en)
IL (1) IL209434D0 (en)
ME (1) ME02340B (en)
MX (1) MX2010013557A (en)
MY (1) MY161369A (en)
NO (1) NO20101688A1 (en)
NZ (1) NZ623922A (en)
PE (2) PE04072014A1 (en)
PT (1) PT2299821E (en)
RS (1) RS54560B1 (en)
RU (2) RU2545023C9 (en)
SI (1) SI2299821T1 (en)
TW (3) TWI449703B (en)
UA (1) UA106045C2 (en)
UY (1) UY31881A (en)
WO (1) WO2009152133A1 (en)
ZA (1) ZA201008562B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI449703B (en) 2008-06-10 2014-08-21 Abbvie Inc Novel tricyclic compounds
US20120034250A1 (en) 2009-04-14 2012-02-09 Astellas Pharma Inc. Condensed pyrrolopyridine derivative
EP3026052A1 (en) * 2009-04-20 2016-06-01 Auspex Pharmaceuticals, Inc. Preparation of deuterated piperidine inhibitors of janus kinase 3
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
TW201120041A (en) 2009-09-10 2011-06-16 Hoffmann La Roche Inhibitors of JAK
ES2509590T3 (en) 2009-09-21 2014-10-17 F. Hoffmann-La Roche Ag JAK macrocyclic inhibitors
EP2493866A1 (en) 2009-10-29 2012-09-05 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
SG181147A1 (en) 2009-12-01 2012-07-30 Abbott Lab Novel tricyclic compounds
CN104370909B (en) * 2009-12-01 2018-09-11 Abbvie 公司 Tricyclic compound
WO2011082267A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrazine compounds
BR112012017269A2 (en) * 2010-01-12 2016-05-03 Hoffmann La Roche tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
DE102011106849A1 (en) * 2010-12-15 2012-06-21 Merck Patent Gmbh Process for the synthesis of N-N linked and around the N-N bond of rotation-inhibited bis-N-heterocyclic carbenes and their use as ligands for metal complexes
TW201309639A (en) * 2011-02-17 2013-03-01 Lg Life Sciences Ltd Oxime derivatives as GPR119 agonists
AU2012232658B2 (en) * 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
JP6278406B2 (en) * 2011-04-21 2018-02-14 オリゲニス ゲーエムベーハーOrigenis Gmbh Heterocyclic compounds as kinase inhibitors
US20120330012A1 (en) * 2011-04-29 2012-12-27 Abbott Laboratories Novel Tricyclic Compounds
AR086113A1 (en) 2011-04-30 2013-11-20 Abbott Lab Isoxazolines as therapeutic agents
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
US9216999B2 (en) 2011-08-12 2015-12-22 Nissan Chemical Industries, Ltd. Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors
WO2014014050A1 (en) 2012-07-19 2014-01-23 大日本住友製薬株式会社 1-(cycloalkyl-carbonyl)proline derivative
EP2895489B1 (en) 2012-09-17 2017-10-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
US9593115B2 (en) * 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
CN102961382B (en) * 2012-11-28 2014-07-16 玉林师范学院 Osteosarcoma cell inhibitor and preparation method thereof
US9475813B2 (en) 2013-02-08 2016-10-25 Nissan Chemical Industries, Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor
JP2016135742A (en) * 2013-03-29 2016-07-28 日本農薬株式会社 Condensed heterocyclic compound or salt thereof and insecticide for agricultural and horticultural use comprising compound, and method for use thereof
WO2014169473A1 (en) * 2013-04-19 2014-10-23 Abbvie Inc. 6H-IMIDAZO[1,5-a]PYRROLO[2,3-e]PYRAZINE COMPOUNDS
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN103694168B (en) * 2013-12-05 2015-08-19 贵州威顿晶磷电子材料股份有限公司 One kind of 6-chloro-4-trifluoromethyl-3-cyanopyridine method
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3144309B1 (en) 2014-05-14 2019-08-14 Nissan Chemical Corporation Tricyclic compound and jak inhibitor
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20170129902A1 (en) 2015-10-16 2017-05-11 Abbvie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
JP6567778B2 (en) 2016-09-26 2019-08-28 中外製薬株式会社 Pyrazolopyridine derivatives having GLP-1 receptor agonist activity
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2019100008A1 (en) * 2017-11-20 2019-05-23 Georgetown University Treatments and methods for controlling hypertension

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1376A (en) * 1839-10-18 Wateb-wheel
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
US3663559A (en) 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA7307247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4053474A (en) * 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE69033614T2 (en) 1989-10-20 2001-04-19 Kyowa Hakko Kogyo Kk condensed purine derivatives
AT271064T (en) 1990-01-11 2004-07-15 Isis Pharmaceuticals Inc to detect oligonucleotide derivatives and modulation of gene expression and activity rna
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
AT201234T (en) 1991-03-18 2001-06-15 Univ New York For human tumor necrosis factor-specific monoclonal and chimeric antibodies
KR100207360B1 (en) 1991-06-14 1999-07-15 돈 더블유. 슈미츠 Imidazon (1,5-a) quinoxalines
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2156918A1 (en) 1993-02-26 1994-09-01 Deen Tulshian 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5736540A (en) 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
RU2158127C2 (en) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Method for inhibiting epidermal growth factor receptor thyrosinekinase, nitrogen-containing tricyclic compounds and pharmaceutical composition for introducing epidermal growth factor receptor thyrosinekinase inhibitor like erb- b2, erb-b3 or erb-b4 and contraceptive composition
IL112248D0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5763137A (en) 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69940808D1 (en) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocycles substituted imidazopyrazine as protein-tyrosine kinase inhibitors
CO5271670A1 (en) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonists corticitropina releasing factor and related compositions
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CN1468241A (en) 2000-08-07 2004-01-14 神经原公司 Heterocyclic compounds as ligands of the gabaa receptor
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
AT353013T (en) 2002-02-19 2007-02-15 Pfizer Italia Srl Tricyclic pyrazole derivatives, processes for their manufacture and their use as antitumor agent
TW200400034A (en) 2002-05-20 2004-01-01 Squibb Bristol Myers Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
JP2006516561A (en) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニーWarner−Lambert Companyllc 2-aminopyridine-substituted heterocyclic compounds as inhibitors of cell proliferation
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06013250A (en) * 2004-05-14 2007-02-28 Abbott Lab Kinase inhibitors as therapeutic agents.
AR049300A1 (en) 2004-06-15 2006-07-12 Schering Corp Tricyclic compounds mGluR1 antagonists as therapeutic agents
EP1773840B1 (en) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituted pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of pda-4 and/or tnf-alpha release
CA2594425A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
EP1844048B1 (en) 2005-01-14 2010-05-26 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
EP1863813A2 (en) * 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
KR20080035698A (en) * 2005-08-16 2008-04-23 더 스크립스 리서치 인스티튜트 Compounds and compositions as protein kinase inhibitors
EA014244B1 (en) 2005-09-23 2010-10-29 Коли Фармасьютикал Груп, Инк. Process for the preparation of 1-H-imidazo [4,5-c] pyridines and their analogues
AU2006316322B2 (en) 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
JP5386350B2 (en) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド Indazole and isoindole derivatives as glucokinase activators
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
JP2010505855A (en) 2006-10-06 2010-02-25 アボット・ラボラトリーズAbbott Laboratories Novel imidazo benzothiazoles and imidazo oxazoles
WO2008084861A1 (en) 2007-01-12 2008-07-17 Astellas Pharma Inc. Condensed pyridine compound
EP2108020A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc Novel triazolopyridazines
CN101939324B (en) 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 PYRROLOPYRAZINE kinase inhibitor
WO2009106445A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
DK2250172T3 (en) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
TWI449703B (en) 2008-06-10 2014-08-21 Abbvie Inc Novel tricyclic compounds
JP2011526931A (en) 2008-07-03 2011-10-20 エグゼリクシス, インコーポレイテッド CDK modulator
US20120034250A1 (en) 2009-04-14 2012-02-09 Astellas Pharma Inc. Condensed pyrrolopyridine derivative
US8361962B2 (en) 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
CN104370909B (en) 2009-12-01 2018-09-11 Abbvie 公司 Tricyclic compound
SG181147A1 (en) 2009-12-01 2012-07-30 Abbott Lab Novel tricyclic compounds
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
US20120330012A1 (en) 2011-04-29 2012-12-27 Abbott Laboratories Novel Tricyclic Compounds
WO2013043826A1 (en) 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors

Also Published As

Publication number Publication date
ECSP10010657A (en) 2011-02-28
CL2010001426A1 (en) 2011-07-15
RU2010153582A (en) 2012-07-20
US20090312338A1 (en) 2009-12-17
CY1117165T1 (en) 2017-04-05
KR101718384B1 (en) 2017-03-22
EP3031324A3 (en) 2016-09-07
US8962629B2 (en) 2015-02-24
CA3000973A1 (en) 2009-12-17
CN102118968A (en) 2011-07-06
CA2727032C (en) 2018-08-14
CO6382083A2 (en) 2012-02-15
EP2299821B1 (en) 2015-11-04
US9365579B2 (en) 2016-06-14
EP3031324A2 (en) 2016-06-15
US20160326181A1 (en) 2016-11-10
JP5748659B2 (en) 2015-07-15
CN104592231A (en) 2015-05-06
PE04072014A1 (en) 2014-04-25
NZ623922A (en) 2015-09-25
HUE028347T2 (en) 2016-12-28
AU2009257602A1 (en) 2009-12-17
TW201002720A (en) 2010-01-16
ME02340B (en) 2017-02-20
JP2012505152A (en) 2012-03-01
DOP2013000055A (en) 2013-04-30
US20150210708A1 (en) 2015-07-30
RU2015105591A (en) 2015-08-10
RU2545023C2 (en) 2015-03-27
NO20101688A1 (en) 2011-03-09
RU2545023C9 (en) 2016-06-20
BRPI0915374A2 (en) 2015-08-04
JP2015163632A (en) 2015-09-10
WO2009152133A1 (en) 2009-12-17
ZA201008562B (en) 2012-05-30
AU2009257602B2 (en) 2015-10-08
CA2727032A1 (en) 2009-12-17
TW201434841A (en) 2014-09-16
PT2299821E (en) 2016-03-11
TWI527819B (en) 2016-04-01
KR20160148053A (en) 2016-12-23
HRP20160098T1 (en) 2016-02-26
RS54560B1 (en) 2016-06-30
RU2015105591A3 (en) 2018-10-10
UY31881A (en) 2010-01-29
MY161369A (en) 2017-04-14
EP2299821A4 (en) 2012-02-08
ES2559403T3 (en) 2016-02-12
TW201612182A (en) 2016-04-01
SI2299821T1 (en) 2016-03-31
DK2299821T3 (en) 2016-02-15
KR20110017431A (en) 2011-02-21
MX2010013557A (en) 2011-03-24
AR072086A1 (en) 2010-08-04
UA106045C2 (en) 2014-07-25
EP2299821A1 (en) 2011-03-30
DOP2010000382A (en) 2018-06-30
IL209434D0 (en) 2011-01-31
HK1155617A1 (en) 2017-06-23
TWI449703B (en) 2014-08-21
US20180291029A1 (en) 2018-10-11
CR20160007A (en) 2016-03-15

Similar Documents

Publication Publication Date Title
TWI327470B (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
CR20130506A (en) Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines Substituted heteroaryl JANUS KINASE INHIBITORS AS (DIVISIONAL EXP. 10065)
MXPA06013114A (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors.
CR20130216A (en) Pyrrolo [2,3-b] pyridine as protein kinase inhibitors
PE08142012A1 (en) Compounds and compositions as protein kinase inhibitors
PE03152008A1 (en) DERIVATIVES pyrazolo [3,4-d] pyrimidines as inhibitors of PI-3 KINASE
CO6251377A2 (en) Imidazo
BRPI0413452A (en) compound, pharmaceutical composition, kit, article of manufacture, and methods of inhibiting DPP-IV, therapeutic and treating a disease state, cancer, autoimmune disorders, HIV condition one einfecção
MXPA06012394A (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer.
SG164279A1 (en) Tricyclic thrombin receptor antagonists
PT2019104E (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
ECSP088345A (en) New pyrazolopyrimidines as kinase inhibitors cyclin dependent
TNSN08089A1 (en) Substituted benzimidazoles and methods of preparation
ECSP11011182A (en) organic compounds
TW200613272A (en) Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
MXPA06001494A (en) Condensed pyramidine compounds as inhibitors of voltage-gated ion channels.
TW200801007A (en) Triazolopyridazines as kinase modulators
TW200500344A (en) Novel compounds
ECSP077276A (en) Aminoheteroaryl compounds enantiomerically puroscomo protein kinase inhibitors
WO2006124863A3 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
RS105204A (en) Substituted 3-amino-thieno/2,3-b/pyridine- 2-carboxylic acid amide compounds and processes for preparing and their uses
TW200526607A (en) Heterocyclic inhibitors of MEK and methods of use thereof
WO2007018998A3 (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
BG108683A (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
UA82420C2 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors

Legal Events

Date Code Title Description
FG Grant, registration